Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Kidney International

• Publication date

  2012-08-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ki.2012.63PMID 22456601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway.

  2011cited by this paper
• Complement factor H deficiency accelerates development of lupus nephritis.

  2011cited by this paper
• Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.

  2011cited by this paper
• Alternative complement pathway assessment in patients with atypical HUS.

  2011cited by this paper
• Heterogeneous pattern of renal disease associated with homozygous factor H deficiency.

  2011cited by this paper
• C3 glomerulopathy: a new classification

  2010cited by this paper
• Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

  2010cited by this paper
• Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.

  2010cited by this paper
• Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.

  2010cited by this paper
• Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.

  2009cited by this paper
• The Binding of Factor H to a Complex of Physiological Polyanions and C3b on Cells Is Impaired in Atypical Hemolytic Uremic Syndrome1

  2009cited by this paper
• Structure of C3b-factor H and implications for host protection by complement regulators

  2009cited by this paper
• Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

  2009cited by this paper
• Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I

  2009cited by this paper
• Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits.

  2008cited by this paper
• Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice.

  2008cited by this paper
• Dense deposit disease is not a membranoproliferative glomerulonephritis

  2007cited by this paper
• Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains

  2007cited by this paper
• Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration.

  2007cited by this paper
• A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.

  2007cited by this paper
• Structure Shows That a Glycosaminoglycan and Protein Recognition Site in Factor H Is Perturbed by Age-related Macular Degeneration-linked Single Nucleotide Polymorphism*

  2007cited by this paper
• MPGN II – genetically determined by defective complement regulation?

  2007cited by this paper
• Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

  2007cited by this paper
• The interactive Factor H–atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models

  2007cited by this paper
• Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.

  2007cited by this paper
• Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk.

  2006cited by this paper
• His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form*

  2006cited by this paper
• Complement Factor H Gene Abnormalities in Haemolytic Uraemic Syndrome: From Point Mutations to Hybrid Gene

  2006cited by this paper
• Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

  2006cited by this paper
• Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome

  2006cited by this paper
• Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)

  2005cited by this paper
• Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.

  2005cited by this paper
• Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.

  2005cited by this paper
• A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.

  2005cited by this paper
• The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts

  2005cited by this paper
• Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

  2005cited by this paper
• Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H

  2002cited by this paper
• Prognostic factors in mesangioproliferative glomerulonephritis.

  2002cited by this paper
• Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long‐term follow‐up

  2001cited by this paper
• Each of the three binding sites on complement factor H interacts with a distinct site on C3b.

  2000cited by this paper
• Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.

  1995cited by this paper
• Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.

  1994cited by this paper
• A simple estimate of glomerular filtration rate in adolescent boys.

  1985cited by this paper
• Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor

  1984cited by this paper
• A simple estimate of glomerular filtration rate in full-term infants during the first year of life.

  1984cited by this paper
• Mesangiocapillary glomerulonephritis: A long‐term study of 40 cases

  1983cited by this paper
• Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis.

  1983cited by this paper
• Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.

  1982cited by this paper
• The prognostic value of some clinical and histological parameters in membranoproliferative glomerulonephritis (MPGN): report of 112 cases.

  1977cited by this paper
• A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

  1976cited by this paper
• Complement deposition in the kidney.

  1974cited by this paper

• Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment.

  2026cites this paper
• C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies.

  2026cites this paper
• Complement 3 Glomerulopathy Revisited: Bridging Pathogenesis and Therapy in the New Era.

  2026cites this paper
• Real-World Analysis of Patients With C3 Glomerulopathy in the United States.

  2026cites this paper
• Guarding glomeruli from immune injury.

  2025cites this paper
• Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry.

  2025cites this paper
• Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: A Significant Cause of End-Stage Kidney Disease in Children

  2025cites this paper
• Kidney damage in patients with multiple myeloma associated with light chain deposition disease and C3 glomerulopathy

  2025cites this paper
• Complement deficiencies and infections.

  2025cites this paper
• Disease Progression in Age-Related Macular Degeneration Patients Carrying Rare Variants in the Complement Factor H or Complement Factor I Genes

  2025cites this paper
• C3 glomerulopathy associated with mycoplasma pneumoniae infection and positive IgA staining

  2025cites this paper
• Factor H-related 1 and heparan sulfate architecture contribute to complement dysregulation in C3 glomerulopathy

  2025cites this paper
• Kidney transplant in patients with C3 glomerulopathy

  2025cites this paper
• Locityper: targeted genotyping of complex polymorphic genes

  2025influential citation
• Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative Glomerulonephritis.

  2025cites this paper
• Chronic kidney disease enhances alternative pathway activity: a new paradigm

  2025cites this paper
• Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

  2025cites this paper
• Complement-Mediated Kidney Disease and Living Donor Transplantation: Tailoring Approaches to Improve Outcomes

  2025cites this paper
• Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations

  2025cites this paper
• Acquired drivers of C3 glomerulopathy

  2025cites this paper
• Revealing the hidden impact of SGLT2 inhibitors on uric acid levels: a retrospective multicenter cohort study

  2025cites this paper
• Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

  2025cites this paper
• Successful Management of C3 Glomerulopathy Recurrence Post-Kidney Transplantation with Iptacopan: A Case Report

  2025cites this paper
• Locityper enables targeted genotyping of complex polymorphic genes

  2025influential citation
• Gene-Environment Interaction: Lessons From Complement-Mediated Kidney Disease.

  2025cites this paper
• Eculizumab in C3 Glomerulopathy: A Systematic Review of Therapeutic Efficacy and Clinical Outcomes

  2025influential citation
• Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy.

  2025cites this paper
• Autoantibodies Against Factor B and Factor H Without Pathogenic Effects in a Patient with Immune Complex-Mediated Membranoproliferative Glomerulonephritis

  2025cites this paper
• Treatment and Disease Burden in Patients with Complement 3 Glomerulopathy: Multinational Real-World Study Results

  2025cites this paper
• Monoclonal gammopathy-associated C3 glomerulonephritis secondary to follicular lymphoma: a case report

  2025cites this paper
• Recurrence of C3 Glomerulopathy and Immune Complex–Mediated Membranoproliferative Glomerulonephritis After Kidney Transplantation: Challenges and Opportunities

  2025cites this paper
• Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation

  2025cites this paper
• Pregnancy outcomes in C3 glomerulopathy: a retrospective review

  2025cites this paper
• A rare co-existence of celiac disease and C3 glomerulopathy.

  2025cites this paper
• IgA Nephropathy With Membranoproliferative Pattern and Resistance to Immunosuppressive Therapy in Two Patients With Cofactor I Pathogenic Variant

  2025cites this paper
• When a NeF Is Not Enough: Improving Assays in C3 Glomerulopathy.

  2025cites this paper
• C3-Glomerulopathie - Herausforderungen in der Diagnose und Therapie

  2025cites this paper
• Atypical presentation of post-streptococcal glomerulonephritis in a child with genetically confirmed susceptibility to C3-glomerulopathy: a case report and brief review of the literature

  2025cites this paper
• Kidney Transplantation in Children and Adolescents With C3 Glomerulopathy or Immune Complex Membranoproliferative Glomerulonephritis: An International Survey of Current Practice

  2025cites this paper
• C3 concentrations can be normal in patients with C3 glomerulopathy secondary to C3 nephritic factor

  2024cites this paper
• The human factor H protein family – an update

  2024cites this paper
• Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy.

  2024cites this paper
• C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation

  2024cites this paper
• Acquired and genetic drivers of C3 and C5 convertase dysregulation in C3 glomerulopathy and immunoglobulin-associated MPGN.

  2024cites this paper
• The Difficulties of Treating Complement-3–Mediated Glomerulopathy

  2024cites this paper
• Glomerulonephritis mit MPGN-Muster und verwandte Formen

  2024cites this paper
• Establishing the Future Direction of Clinical Outcomes in C3 Glomerulopathy: Perspectives From a Patient and a Physician

  2024cites this paper
• Functional Characterization of Anti-C3bBb Autoantibodies and C3 Glomerulopathy Phenotype

  2024cites this paper
• Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy

  2024cites this paper
• Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGN.

  2024cites this paper
• To interpret and analyze the changing patterns of histology and direct immunofluorescence findings in membranoproliferative glomerulonephritis

  2024cites this paper
• C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation

  2024cites this paper
• Update on C3 Glomerulopathy.

  2024cites this paper
• C3 Glomerulopathy: A Current Perspective in an Evolving Landscape

  2024influential citation
• Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network

  2024cites this paper
• Clinical features and outcomes of immune complex-membranoproliferative glomerulonephritis and C3 glomerulopathy: a multicenter observational cohort study analyzing kidney biopsy cases.

  2024cites this paper
• C3 glomerulopathy in children: experience at a resource-limited center

  2024cites this paper
• The Role of Complement in Kidney Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

  2024cites this paper
• Clinical and pathological features of 52 patients with glomerulonephritis with dominant C3.

  2024cites this paper
• Complément dans les glomérulopathies à dépôts de C3 : exploration et conséquences thérapeutiques

  2024cites this paper
• Diagnostic Challenges and Emerging Pathogeneses of Selected Glomerulopathies

  2024cites this paper
• Balancing efficacy and safety of complement inhibitors.

  2024cites this paper
• Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review

  2024cites this paper
• Recurrent C3 glomerulopathy after kidney transplantation.

  2024cites this paper
• Prognostic factors and validation of the histologic chronicity score for C3 glomerulopathy: a registry analysis

  2024cites this paper
• Complement Activation in Nephrotic Glomerular Diseases

  2024cites this paper
• Unsupervised Clustering of Membranoproliferative Glomerulonephritis and C3 Glomerulopathy Patients Discovers Distinct Patient Groups unlike the Current Classification

  2024cites this paper
• Clinical Remission and Reduction of Circulating Nephritic Factors by Combining Rituximab With Belimumab in a Case of Complement Factor 3 Glomerulopathy

  2024cites this paper
• Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

  2024cites this paper
• Comprehensive review of membranoproliferative glomerulonephritis: spotlighting the latest advances in revised classification and treatment

  2023cites this paper
• Complement gene mutations in children with C3 glomerulopathy: do they affect the response to mycophenolate mofetil?

  2023influential citation
• C3 Glomerulopathy: Novel Treatment Paradigms.

  2023cites this paper
• Morphological and etiological analyses of C3 and non-C3 glomerulonephritis in primary membranoproliferative glomerulonephritis using periodic acid-methenamine silver stain electron microscopy: a retrospective multicentered study

  2023cites this paper
• Iptacopan in Idiopathic Immune Complex–Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study

  2023cites this paper
• Functional Magnetic Resonance Imaging to Monitor Disease Progression: A Prospective Study in Patients with Primary Membranoproliferative Glomerulonephritis

  2023cites this paper
• The role of complement in kidney disease

  2023cites this paper
• Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

  2023cites this paper
• Hypertensive retinopathy and Purtscher-like retinopathy in a child with complement 3 glomerulopathy.

  2023cites this paper
• Genetic investigation of Nordic patients with complement-mediated kidney diseases

  2023cites this paper
• Komplementvermittelte seltene Glomerulonephritis(GN)-Formen

  2023cites this paper
• C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis

  2023cites this paper
• Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies

  2023cites this paper
• Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic.

  2023cites this paper
• Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation.

  2023cites this paper
• Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN

  2023cites this paper
• C3 glomerulopathy.

  2023cites this paper
• C3 Glomerulopathy With Concurrent Thrombotic Microangiopathy: Clinical and Immunological Features.

  2023cites this paper
• Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy

  2023cites this paper
• HTNpedia: A Knowledge Base for Hypertension Research.

  2023cites this paper
• Spatially resolved transcriptomic profiling for glomerular and tubulointerstitial gene expression in C3 glomerulopathy

  2023cites this paper
• Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases

  2023cites this paper
• Successful treatment with avacopan (CCX168) in a pediatric patient with C3 glomerulonephritis

  2023cites this paper
• Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

  2023influential citation
• Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy

  2023cites this paper
• Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface

  2023cites this paper
• Deficiências primárias do sistema complemento e seus mimetizadores: vasculite urticária hipocomplementêmica e glomerulopatias C3

  2023cites this paper
• Comparison of dominant and nondominant C3 deposition in primary glomerulonephritis

  2023cites this paper
• The role of the mesangium in glomerular function

  2023cites this paper
• C3 glomerulopathy: Understanding an ultra‐rare complement‐mediated renal disease

  2022influential citation
• Results from a national-wide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy.

  2022cites this paper